Has Acemini been launched in the country? When will it be launched in China?

Asciminib, chemical nameAsciminib, is a drug developed specifically for the treatment of chronic myelogenous leukemia (CML). Through a unique mechanism of action, it provides a new treatment avenue for patients who have been treated with two or more tyrosine kinase inhibitors (TKIs) but have failed to respond. As the first and only specific target inhibitor (STAMP), Aceminib can precisely act on the ABL acyl pocket to block the growth and spread of leukemia cells.

In clinical trials, Aceminib’s efficacy has been impressive. For example, in a pivotal study, patients treated with aximinib had nearly double the molecular response rate at 24 weeks compared with another drug, bosutinib. Long-term follow-up data also show that with the extension of treatment time, the efficacy of aceminib is not only maintained, but even improved, and its safety has also been widely recognized.

In addition to its high efficacy, aceminib is also well tolerated and has relatively few side effects, which greatly improves patients' quality of life. Common side effects include nausea, vomiting, diarrhea, and fatigue, but these symptoms can usually be relieved with appropriate medical management.

Aximini has not yet been officially launched in China, so domestic patients cannot directly purchase this drug yet. As far as we know, the original version of Acemini is quite expensive. A package of 60 tablets of 40mg costs about 150,000 yuan. However, generic versions of Asiminib are already available in overseas markets. Among them, the version produced by Lucius Pharmaceuticals in Laos is relatively low-priced, with the same specifications priced at only about 4,500 yuan. If you need further information about Acemini, it is recommended to consult a professional overseas medical consulting company.

In general, as a new type of CML treatment drug, aceminib brings new hope to leukemia patients with its unique mechanism of action and significant clinical effects.